FDA decision on REMS would encourage better treatment access

Abstract

The Food and Drug Administration (FDA) last month announced that it would no longer require prescribers, pharmacies or patients to participate in the risk evaluation and mitigation strategy (REMS) program, which required a blood test prior to dispensing clozapine, an antipsychotic medication, considered a “gold standard” treatment for people with schizophrenia.